Upcoming catalysts for the third quarter of 2021 include approval decisions by the US Food and Drug Administration (FDA) on teplizumab for the treatment of type 1 diabetes (T1D), anifrolumab for the treatment of systemic lupus erythematosus  (SLE) and oportuzumab monatox for the treatment of bladder cancer.

Para acessar a publicação na íntegra clique aqui